Market brief
Viral Vector CDMO Europe 2026: AAV, Adenovirus, Lentivirus
European viral vector CDMO capacity in 2026 is concentrated at a small number of specialised operators rather than spread across every biologics CDMO. FinVector in Kuopio, Finland operates clinical-to-commercial viral vector manufacturing. The Kuopio Center for Gene and Cell Therapy adds GMP AAV, adenovirus, and lentivirus CDMO services at clinical scale. 3PBIOVIAN in Turku provides biologics + viral vectors + plasmid DNA. IDT Biologika in Dessau-Rosslau, Germany runs viral vaccines and cell-and-gene-therapy fill-finish at commercial scale. Fuse Vectors in Copenhagen is developing a cell-free viral vector manufacturing platform targeting AAV scalability — pre-GMP platform stage, not yet a contracting CDMO. Together, these four operating CDMOs plus one platform-stage developer form the European viral vector CDMO layer the directory surfaces. Around them, clinical-stage cell and gene therapy companies (T-Knife, Anocca, Elicera, RHEACELL, PolTREG, Antion, Froceth, and others) provide end-user demand and sometimes internal manufacturing capacity. The European CDMO Capacity 2026 brief covers the wider CDMO landscape.
Summary
Key findings
Finland is the highest operator count for viral vector manufacturing in the directory — FinVector (Kuopio) and the Kuopio Center for Gene and Cell Therapy (Kuopio) as dedicated viral vector CDMOs, 3PBIOVIAN (Turku) as a biologics CDMO with viral vector scope, and Rokote Laboratories (Kuopio) as a nasal adenoviral-vaccine clinical-stage programme.
IDT Biologika (Dessau-Rosslau, Germany) is the German viral vaccines + cell-and-gene-therapy fill-finish CDMO the directory surfaces at commercial scale. Its specialisation leans vaccine-first, with viral vector capability as part of the cell-and-gene-therapy services scope.
Fuse Vectors (Copenhagen, Denmark) is a pre-GMP platform-stage developer of cell-free viral vector manufacturing for AAV — not yet a contracting CDMO, but the European directory entry publicly working on the cell-free AAV route.
Clinical-stage cell and gene therapy demand comes from 18+ operators across Germany (T-Knife, RHEACELL, Miltenyi Biotec, TolerogenixX), the Nordics (Anocca, Elicera, Verigraft, Xintela, Zelluna), Poland (PolTREG, Bioceltix), Switzerland (Antion Biosciences), and Lithuania (Froceth).
Numbers
Quick numbers
Analysis
Finland: the highest viral vector operator count
Finland holds the most viral vector manufacturing operators in the directory. FinVector in Kuopio runs clinical-to-commercial viral vector manufacturing — the dedicated viral vector CDMO the directory surfaces at that scale in Europe. The Kuopio Center for Gene and Cell Therapy adds GMP AAV, adenovirus, and lentivirus CDMO services alongside ATMP clinical-stage capacity. 3PBIOVIAN in Turku provides a broader biologics CDMO service that includes viral vectors and plasmid DNA — useful for sponsors wanting one operator across biologics + viral vector + pDNA. Rokote Laboratories Finland in Kuopio runs nasal adenoviral-vector vaccine programmes at Phase 1 scope. Together, Finland is the European geography with the highest viral vector operator count the directory surfaces, and Kuopio specifically holds the highest operator count per city.
Analysis
Germany: IDT Biologika at commercial scale
In Germany, IDT Biologika in Dessau-Rosslau is the viral vaccines + cell-and-gene-therapy + fill-finish CDMO the directory surfaces at commercial scale. Its public specialisation leans vaccines first, with viral vector capability sitting inside the cell-and-gene-therapy services scope. For sponsors planning viral vector programmes with an already-established EU biologics CDMO partner, IDT Biologika is the German option in the directory. Miltenyi Biotec in Bergisch Gladbach provides cell therapy platforms and clinical manufacturing tools adjacent to viral vector workflows; it is not a viral vector CDMO but supports gene therapy programmes as a tools and services supplier.
Analysis
Denmark: Fuse Vectors and the cell-free AAV bet
Fuse Vectors in Copenhagen is developing a cell-free viral vector manufacturing platform focused on AAV scalability. The directory classifies the company as a pre-GMP platform-stage biotech rather than a contracting CDMO — it is not yet operating commercial or clinical-scope viral vector services. Cell-free AAV manufacturing is a distinct technology route compared to traditional cell-based production at FinVector or IDT Biologika, and a scaling-frontier bet rather than a ready-to-contract option. For sponsors tracking European viral vector supply beyond current CDMO capacity, Fuse Vectors is the directory entry publicly working on the cell-free AAV problem. Maturity, clinical validation, and regulatory posture must be verified directly.
Analysis
Where the clinical-stage demand sits
European viral vector CDMO demand comes from a broad clinical-stage cell and gene therapy layer. Germany hosts T-Knife (Berlin, TCR-T cell therapy), RHEACELL (Heidelberg, stromal cell therapy), Miltenyi Biotec (tools), and TolerogenixX (Heidelberg, tolerogenic dendritic cells). Sweden has Anocca (Sodertalje, TCR-T cell therapy), Elicera Therapeutics (Gothenburg, CAR-T and oncolytic viruses), Verigraft (Gothenburg, tissue engineering ATMPs), and Xintela (Lund, stem cell therapy). Norway adds Zelluna (Oslo, TCR-NK cell therapy). Poland hosts PolTREG (Gdansk, regulatory T-cell therapy) and Bioceltix (Wroclaw, veterinary cell therapy). Switzerland has Antion Biosciences (Geneva, multiplex gene silencing + allogeneic CAR-T). Lithuania has Froceth (Vilnius, adipose-derived cell therapy ATMP). Most of these operators run in-house or partner-based manufacturing; the CDMO layer serves the ones scaling beyond internal capacity.
Analysis
Technology split: cell-based vs cell-free, AAV vs adenoviral vs lentiviral
Viral vector CDMO choice in Europe in 2026 depends on three technology axes. First, manufacturing mode: traditional cell-based production (FinVector, IDT Biologika, Kuopio Center, 3PBIOVIAN) vs. cell-free (Fuse Vectors, platform-stage). Cell-based covers all current commercial scope; cell-free is the scaling-frontier bet that has not yet reached commercial contracting. Second, vector class: AAV (FinVector, Kuopio Center, Fuse Vectors target), adenoviral (FinVector, Kuopio Center, IDT Biologika for vaccines, Rokote clinical), lentiviral (Kuopio Center). Third, scale: clinical-to-commercial (FinVector, IDT Biologika) vs. clinical (Kuopio Center, 3PBIOVIAN) vs. pre-GMP platform (Fuse Vectors). For sponsors, the practical question is which vector class + which scale + which manufacturing mode combination fits the specific programme.
Analysis
Supply chain and logistics
Viral vector manufacturing is cold-chain-heavy and requires GDP-certified logistics for clinical and commercial shipments. The same operators that cover European biologics logistics (DHL Life Sciences & Healthcare, Kuehne+Nagel Healthcare, World Courier) serve viral vector movement across EU-internal and Nordic-to-continental lanes. Raw material supply for viral vector programmes (plasmid DNA, cell lines, reagents) pulls from the general European biologics supply chain, with 3PBIOVIAN providing in-house pDNA alongside viral vector manufacturing.
What to watch
What to watch next
FinVector capacity expansion and new programme announcements
Kuopio Center for Gene and Cell Therapy scaling beyond clinical
IDT Biologika viral vector capacity announcements following COVID-era expansion
Fuse Vectors cell-free AAV process-maturity milestones and first commercial programmes
New European viral vector CDMO entrants — most likely spin-outs from existing biologics CDMOs
FAQ
Frequently asked questions
Who runs European viral vector CDMO work in 2026?
FinVector in Kuopio, Finland is the European dedicated viral vector CDMO the directory surfaces at clinical-to-commercial scale. The Kuopio Center for Gene and Cell Therapy (Kuopio) provides GMP AAV, adenovirus, and lentivirus services at clinical scale. 3PBIOVIAN in Turku adds a biologics + viral vectors + pDNA CDMO service. IDT Biologika in Dessau-Rosslau, Germany operates viral vaccines plus cell-and-gene-therapy fill-finish at commercial scale (vaccine-first specialisation). Fuse Vectors in Copenhagen is developing a cell-free AAV manufacturing platform — pre-GMP, not yet a contracting CDMO. Together, four operating CDMOs plus one platform-stage developer form the European viral vector CDMO layer the directory surfaces.
Where can I find lentiviral CDMO capacity in Europe?
The Kuopio Center for Gene and Cell Therapy in Kuopio, Finland is the European operator in the directory with published lentivirus CDMO services alongside AAV and adenoviral. For cell therapy programmes using lentiviral vectors, Kuopio Center is the directory entry with explicit lentivirus scope.
What is Fuse Vectors’ cell-free AAV approach?
Fuse Vectors in Copenhagen is developing a cell-free viral vector manufacturing platform focused on AAV scalability. Instead of producing AAV in living cells (the conventional route used by FinVector and others), cell-free manufacturing synthesises AAV capsids and packages them in an enzymatic reaction. It is a newer technology targeting the scaling limits of cell-based AAV production, currently at pre-GMP platform stage in the directory classification. Sponsors should verify current process-maturity status, clinical validation, and regulatory posture directly with the company before counting on it as contracting capacity.
How does the European viral vector CDMO layer compare to the US?
The US has a larger viral vector CDMO layer in absolute operator count (Catalent, Lonza Houston, Thermo Fisher, Oxford Biomedica US, etc., most outside the scope of this directory). Europe is smaller but holds differentiated operators: FinVector as a clinical-to-commercial AAV / adenoviral CDMO, IDT Biologika as a vaccine-plus-viral-vector operator, Fuse Vectors as a cell-free technology route. For EU-market commercial launches, running viral vector manufacturing inside Europe removes a cross-regulatory layer and aligns with EMA-led clinical programmes.
Are viral vector CDMOs capacity-tight in 2026?
Public capacity data is not disclosed consistently across operators, but viral vector CDMO capacity has been under meaningful pressure since 2021, particularly AAV at clinical and commercial scale. Sponsors should contact operators early in the programme timeline — 6–18 months of lead time on CDMO slot booking is typical for AAV and adenoviral commercial-scale work. The European viral vector CDMO capacity question is less about which operator is available and more about whose slot aligns with the sponsor’s specific programme timeline.
Methodology note
Sources and interpretation
Sources: verified Memel Biotech directory entries for each viral vector CDMO, official company capability pages, and public regulatory disclosures. The directory entry for each operator links to the authoritative company sources.
Disclaimer
Use limits
This brief is an editorial map of visible European viral vector CDMO capacity in 2026. Capacity availability, pricing, and open slots are not published by operators in a reliable way and change continuously. Sponsors should verify directly with each operator before engagement.
Primary sources
Source list
Related pages
Related directory records
Briefs
Continue through related topics.
A useful brief should help people move into related records, cities, categories, and methodology pages without falling back into generic template language.